mebendazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anthelminthics, tiabendazole derivatives 1641 31431-39-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mebendazole
  • vermox
A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
  • Molecular weight: 295.30
  • Formula: C16H13N3O3
  • CLOGP: 3.08
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 84.08
  • ALOGS: -3.87
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 15 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 28, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 116.26 49.11 40 334 108172 46577516

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC P02CA01 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTHELMINTICS
ANTINEMATODAL AGENTS
Benzimidazole derivatives
ATC P02CA51 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTHELMINTICS
ANTINEMATODAL AGENTS
Benzimidazole derivatives
FDA EPC N0000175481 Anthelmintic
MeSH PA D000871 Anthelmintics
MeSH PA D000890 Anti-Infective Agents
MeSH PA D050256 Antimitotic Agents
MeSH PA D000969 Antinematodal Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D050257 Tubulin Modulators
CHEBI has role CHEBI:35444 antinematodals
CHEBI has role CHEBI:60832 tubulin modulators
CHEBI has role CHEBI:61951 microtubule destabilising role

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ascariasis indication 2435008 DOID:456
Trichuriasis indication 3752003
Enterobiasis indication 266162007
Ancylostoma Duodenale Infection indication
Necator Americanus Infection indication
Infection by Gnathostoma off-label use 44086001 DOID:11379
Capillaria infection off-label use 52979002 DOID:12474
Echinococcus granulosus infection off-label use 75006000 DOID:1495
Echinococcus multilocularis off-label use 86648009
Infection by larvae of Trichinella spiralis off-label use 88264003
Angiostrongyliasis due to Angiostrongylus cantonensis off-label use
Angiostrongyliasis due to Angiostrongylus costaricensis off-label use
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.61 acidic
pKa2 13.2 acidic
pKa3 2.93 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase ABL1 Kinase Ki 5.34 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.44 CHEMBL
Tubulin Structural INHIBITOR CHEMBL CHEMBL
Tubulin Structural INHIBITOR CHEMBL CHEMBL
Calmodulin-domain protein kinase 1 Kinase IC50 6.17 CHEMBL

External reference:

IDSource
4019270 VUID
N0000147469 NUI
D00368 KEGG_DRUG
4019270 VANDF
C0025023 UMLSCUI
CHEBI:6704 CHEBI
CHEMBL685 ChEMBL_ID
D008463 MESH_DESCRIPTOR_UI
DB00643 DRUGBANK_ID
2942 INN_ID
81G6I5V05I UNII
4030 PUBCHEM_CID
202972 RXNORM
1672 MMSL
5026 MMSL
789 MMSL
d00154 MMSL
002987 NDDF
387311004 SNOMEDCT_US
56059005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VERMOX HUMAN PRESCRIPTION DRUG LABEL 1 50458-675 TABLET, CHEWABLE 500 mg ORAL NDA 27 sections
MEBENDAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 54868-3732 TABLET, CHEWABLE 100 mg ORAL ANDA 21 sections
Emverm HUMAN PRESCRIPTION DRUG LABEL 1 64896-669 TABLET, CHEWABLE 100 mg ORAL ANDA 26 sections